VivaxGEN statistics

To access cutting-edge analytics on consensus tools, life science contexts and associated fields, you will need to subscribe to our premium service.


Citations per year

Citations chart

Popular tool citations

chevron_left Microsatellite detection chevron_right
Popular tools chart

Tool usage distribution map

Tool usage distribution map

Associated diseases

Associated diseases

VivaxGEN specifications


Unique identifier OMICS_26424
Name VivaxGEN
Interface Web user interface
Restrictions to use None
Computer skills Basic
Stability Stable
Maintained Yes


  • person_outline Sarah Auburn <>

Publication for VivaxGEN

VivaxGEN in publications

PMCID: 5504659
PMID: 28693552
DOI: 10.1186/s12936-017-1912-y

[…] products were sized by denaturing capillary electrophoresis on an abi 3100 genetic analyzer with genescan liz-600 (applied biosystems) internal size standards. genotype calling was undertaken using vivaxgen version 1.0 []. an arbitrary fluorescent intensity threshold of 100 relative fluorescence units was applied for peak detection, and minor alleles were only called if they had a minimum 33% […]

PMCID: 4094906
PMID: 25008859
DOI: 10.1186/1475-2875-13-262

[…] china shared identical haplotypes to any of the central isolates, evidence for the utility of the marker panel for detecting imported cases was limited. a recently developed data analysis platform (vivaxgen) has been made available for enhanced comparison of str-based p. vivax data between studies []. this multi-centre approach enables data sharing between central china and other p. vivax […]

To access a full list of publications, you will need to upgrade to our premium service.

VivaxGEN institution(s)
Eijkman Institute for Molecular Biology, Jakarta Pusat, Indonesia; Agency for Assessment and Application of Technology, Jakarta Pusat, Indonesia; Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK; The Ministry of Research, Technology and Higher Education, Jakarta Pusat, Indonesia; Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia; College of Natural Sciences, Addis Ababa University, Addis Ababa, Ethiopia; Armauer Hansen Research Institute, Addis Ababa, Ethiopia; Division of Malaria and Parasitic Diseases, National Institute of Health, Korea CDC, Osong, Korea; Department of Parasitology and Tropical Medicine, Kyungpook National University School of Medicine, Daegu, Korea; Royal Center for Disease Control, Department of Public Health, Ministry of Health, Thimphu, Bhutan; Medical College of Soochow University, Suzhou, China; Key Laboratory of National Health and Family Planning Commission on Parasitic Disease Control and Prevention, Jiangsu Provincial Key Laboratory on Parasite and Vector Control Technology, Jiangsu Institute of Parasitic Diseases, Wuxi, China; Drug Resistance and Diagnostics, Army Malaria Institute, Brisbane, QLD, Australia; The AMI Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia; Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK; Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
VivaxGEN funding source(s)
Supported by a Wellcome Trust Senior Research Fellowship in Clinical Science [grant number 200909], the Bill and Melinda Gates Foundation [grant number OPP1164105], the Asia Pacific Malaria Elimination Network through funding from the Australian Department of Foreign Affairs and Trade, the Wellcome Trust (Ref. 100217/Z/12/A), the UK Medical Research Council (Ref. MR/K000551/1) and the UK Medical Research Council (Grant no. MR/ K000551/1, MR/M01360X/1, MR/N010469/1).

VivaxGEN reviews

star_border star_border star_border star_border star_border
star star star star star

Be the first to review VivaxGEN